Pricing Log in Create free account
Friday 6 November 2026 Export MXCT’s income statement to Excel — free account

MaxCyte, Inc.

MXCT Healthcare Medical Devices

MaxCyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.0 million, down 14.5% from fiscal 2024.

Revenue
−14.5%
EPS
+33.3%
Free cash flow
+54.7%

Quarter to June 2026, against a year earlier

1.30 0.01 −0.76%
Market cap
$135.2M
P/E
0.0×
Fwd P/E
−5.8×
Dividend yield
—
F-score
2/9
Altman Z
1.32
Beneish M
−2.89
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.01
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — 1 — — — — — — — —
Insider Ownership 11.24%

Capital & Financial Ratios $m

Size
Market Cap 135.20
Revenue ttm 31.05
Net income ttm (35.64)
Free cash flow ttm (23.64)
Net debt Q (105.69)
Valuation
P/E 0.00
Forward P/E (5.80) (negative: loss-making)
Price / sales 4.51
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.88
Financial health
Current ratio Q 12.26 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (4.24)
Growth
Revenue growth Q −14.53% (below 0%: shrinking)
Operating income growth Q +28.08% (above 0%: growing)
EPS, this year +34.78% (at or above 15%: strong)
EPS, next year A +6.91%
Revenue, next year A −2.50% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +17.03% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.3×, against a ten-year median of 6.5×; over the ten years it ranged from −0.8× in 2026 to 47.5× in 2021.
P/S against its own 10 years 14.50%
10-year low 10-year high
P/B against its own 10 years 13.43%
10-year low 10-year high
EV/Sales against its own 10 years 10.30%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 168 154 103 106
Receivables 6 5 4 4
Inventory 12 9 8 8
Other — — — 0
190 172 118 121
2023 2024 2025 Q'26
Payables 1 1 1 2
ST’ Debt — — — —
Other — — — —
18 16 14 10

Compound Annual Growth %

10y 5y 3y
Sales — 4.76% (9.30%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 38.85% (12.27%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.12 Actual −0.08

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.11 −0.12 Miss by 0.01
Q4 FY25 −0.08 −0.06 Beat by 0.02
Q1 FY26 −0.10 −0.04 Beat by 0.06
Q2 FY26 −0.12 −0.08 Beat by 0.04
Q3 FY26 −0.08 — Reports 10 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.04) (0.08) — — —
’25 (0.10) (0.12) (0.12) (0.09) (0.42)
’24 (0.09) (0.09) (0.11) (0.10) (0.39)
’23 (0.11) (0.10) (0.11) (0.05) (0.37)
’22 (0.04) (0.08) (0.06) (0.05) (0.23)
’21 (0.09) (0.05) (0.03) (0.05) (0.21)
’20 (0.05) (0.05) (0.04) (0.03) (0.17)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 10 7 — — —
’25 10 9 7 7 33
’24 11 10 8 9 39
’23 9 9 8 16 41
’22 12 10 11 12 44
’21 6 7 10 10 34
’20 6 5 7 9 26
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (8) (5) — — —
’25 (14) (10) (7) (3) (34)
’24 (11) (5) (4) (8) (28)
’23 (4) (10) (8) 1 (22)
’22 (4) 1 (6) (6) (15)
’21 (5) (4) (1) (1) (11)
’20 (5) (1) (1) (2) (9)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (8) (5) — — —
’25 (15) (10) (8) (3) (36)
’24 (11) (5) (5) (8) (29)
’23 (6) (11) (9) 0 (25)
’22 (10) (6) (9) (281) (306)
’21 (5) (5) (2) (267) (279)
’20 (6) (1) (1) (2) (11)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 11 19 21 22 26 34 44 41 39 33 31 +12.7% 32 37 44 +9.9%
Gross margin, % 89.34 89.61 88.96 88.44 89.43 89.24 88.48 88.51 81.62 81.16 79.23 (8.2) pt
EBT (3) (13) (11) (13) (12) (19) (24) (38) (41) (45) (36) +34.7%
EBT margin, % (27.27) (70.91) (53.21) (59.64) (45.15) (56.30) (53.25) (91.85) (106.29) (135.14) (114.77) (107.9) pt
Net income (3) — (11) (13) (12) (19) (24) (38) (41) (45) (36) +34.7%
Per share, $
Per share, $ Revenue 0.34 0.39 0.42 0.38 0.38 0.37 0.44 0.40 0.37 0.31 0.29 (0.8%)
Earnings (0.11) (0.27) (0.22) (0.23) (0.17) (0.21) (0.23) (0.37) (0.39) (0.42) (0.33) +15.9%
Cash flow (0.06) (0.27) (0.26) (0.16) (0.13) (0.12) (0.15) (0.21) (0.26) (0.32) (0.22) +19.8%
Capex 0.00 0.00 0.00 (0.02) (0.03) (2.96) (2.86) (0.04) (0.02) (0.02) (0.01) n/m
Free cash flow (0.06) (0.27) (0.26) (0.18) (0.16) (3.08) (3.01) (0.25) (0.28) (0.34) (0.22) +20.4%
Book value 0.15 0.54 0.31 0.24 0.48 2.90 2.50 2.25 1.97 1.61 1.49 +30.0%
Shares, m 34 49 51 56 69 91 102 103 105 106 107 +13.7%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 0.00 0.00 0.00 0.00 16.27 27.24 11.76 12.51 11.29 5.00 4.51 8.4
P/B 0.00 0.00 0.00 0.00 12.82 3.51 2.05 2.22 2.11 0.96 0.88 2.4
EV/Sales 0.00 0.00 0.00 0.00 15.13 19.86 6.74 8.55 7.42 2.02 1.26 6.0
EV/FCF 0.00 0.00 0.00 0.00 (36.48) (2.41) (0.98) (13.91) (9.79) (1.85) (1.66) (6.5)
Cash, $m
Cash, $m Operating cash flow (2) (13) (13) (9) (9) (11) (15) (22) (28) (34) (23) +36.2%
Capex 0 (1) (1) (1) (2) (269) (291) (4) (2) (2) (1) +27.4%
Free cash flow (2) (13) (13) (10) (11) (279) (306) (25) (29) (36) (24) +36.9%
Balance, $m
Balance, $m Working capital 10 31 20 15 34 255 237 172 156 104 111 +29.5%
Net debt (7) (27) (12) (12) (30) (255) (227) (168) (154) (103) (106) +35.4%
Shareholders’ equity 5 26 16 14 33 263 254 232 206 171 159 +47.9%
Returns, %
Returns, % ROA (14.86) (166.91) (48.21) (42.21) (28.90) (11.36) (8.26) (13.67) (16.17) (20.20) (17.62) (5.3) pt
ROIC 0.00 0.00 0.00 (434.02) (204.47) (144.75) (64.22) (47.26) (61.81) (47.39) (49.23) (47.4) pt
ROE (28.58) (84.92) (53.85) (87.88) (50.47) (12.89) (9.12) (15.60) (18.73) (23.63) (20.39) +4.9 pt
People
People Employees — — — — 65 84 125 143 114 91 — +7.0%
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.40 0.40 0.35 0.29 0.34 0.36 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

MaxCyte, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RXST RxSight, Inc. $190.4M — (loss-making) — (loss-making) −18.97% (below 0%: shrinking) n/m +2,591.06% (above 0%: growing) 73.62% (75.32%) Compare
STIM Neuronetics, Inc. $185.2M — (loss-making) — (loss-making) +12.51% (above 0%: growing) n/m +237.71% (above 0%: growing) 52.17% 1.29% Compare
INGN Inogen, Inc $179.7M — (loss-making) — (loss-making) +3.04% (above 0%: growing) n/m −51.15% (below 0%: shrinking) 45.51% (5.36%) Compare
MXCT MaxCyte, Inc. $135.2M — (loss-making) — (loss-making) −14.53% (below 0%: shrinking) n/m +54.74% (above 0%: growing) 76.96% (140.72%)
QTRX Quanterix Corporation $130.5M — (loss-making) — (loss-making) +34.44% (above 0%: growing) n/m +18.92% (above 0%: growing) 38.52% (150.22%) Compare
APYX Apyx Medical Corporation $128.9M — (loss-making) — (loss-making) +8.95% (above 0%: growing) n/m +53.17% (above 0%: growing) 64.16% (4.07%) Compare
OWLT Owlet, Inc. $123.9M — (loss-making) — (loss-making) +29.94% (above 0%: growing) n/m +55.74% (above 0%: growing) 64.44% 5.14% Compare
LUNG Pulmonx Corporation $111.5M — (loss-making) — (loss-making) +6.20% (above 0%: growing) n/m +61.33% (above 0%: growing) 76.19% (32.80%) Compare
CATX Perspective Therapeutics, Inc. $90.0M — (loss-making) — (loss-making) −72.07% (below 0%: shrinking) n/m −66.09% (below 0%: shrinking) 100.00% (36,120.99%) Compare
Median of peers $129.7M — — +7.58% — +54.46% 64.30% (19.08%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 29 April 2026

Ownership

Directors and executive officers, together 4.10%
Capricorn Fund Managers Ltd 7.70%
BlackRock, Inc. 6.50%
River Global Investors LLP 5.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

MaxCyte, Inc. (MXCT) Latest News

28 Oct

Impact 3 · · GlobeNewswire

14 Oct

Impact 4 · · GlobeNewswire

23 Sep

Impact 3 · · GlobeNewswire

19 Aug

Impact 4 ·
Impact 3 · · The Motley Fool transcript

13 Aug

Impact 4 · transcript

12 Aug

Impact 4 · · Moby transcript
Impact 3 · · MarketBeat
Impact 3 ·

21 Jul

Impact 4 ·

23 Jun

Impact 3 · · Business Wire

13 May

Impact 3 · · GuruFocus.com

12 May

Impact 4 · · Moby
Impact 3 · · MarketBeat
Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

25 Mar

Impact 4 · · Moby

24 Mar

Impact 4 · · The Motley Fool transcript
Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire
Impact 3 · · GuruFocus.com
Impact 3 · · Zacks

23 Mar

Impact 3 · · GlobeNewswire

25 Feb

Impact 4 ·

24 Feb

Impact 4 · · GlobeNewswire

12 Jan

Impact 4 · · GlobeNewswire

1 Dec

Impact 3 · · Business Wire

13 Nov

Impact 4 ·

12 Nov

Impact 3 · · GlobeNewswire

5 Nov

Impact 3 · · GlobeNewswire
stockrow.com/MXCT · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com